Preventing infections in patients with blood cancer through evidence-based use of immunoglobulin or alternatives: The RATIONALISE trial

血癌患者，由于抗体水平低和其他疾病或治疗因素导致免疫缺陷，有感染危及生命的风险。从血浆中制备的免疫球蛋白（IG）可以补充抗体水平。政府标准建议对病情稳定的患者停止IG治疗，但没有证据表明何时或如何停止。RATIONALISE将提供这些证据，以改善患者结局，降低风险和成本，并为社区更好地利用血液制品。

Patients with blood cancers, with immune deficiency from low antibody levels and other disease or treatment factors, are at risk of life-threatening infection. Immunoglobulins (Ig) made from plasma can supplement antibody levels. Government criteria recommend stopping Ig therapy in stable patients, but with no evidence for when or how to do so. RATIONALISE will provide this evidence, to improve patient outcomes, reduce risks and costs, and make better use of blood products for the community.